Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Simnova Biotech secures $59.5M Series B led by Fortera Capital and Pudong Venture Capital to advance off-the-shelf cell therapies.
PRIVATESep 06, 2026•about 17 hours ago
Amount Raised
$59.5 Million
Round Type
Series B
ShanghaiBiotechnology
Investors
Youshan CapitalOriza HoldingsCenova VenturesPudong Venture CapitalFortera Capital
Description
Simnova Biotech has secured nearly CNY400 million (USD59.5 million) in its Series B funding round co-led by Shanghai state-owned investment funds Fortera Capital and Pudong Venture Capital, along with private equity firm Cenova Ventures. The funding will accelerate clinical research for the company's off-the-shelf cell therapies, particularly its lead CAR-NK program SNC103 and In Vivo CAR-T platform SNC116. Suzhou state-owned investment firm Oriza Holdings participated as a follow-on investor, while existing shareholder Youshan Capital increased its investment. Founded in 2019, Simnova focuses on off-the-shelf CAR-NK, In Vivo CAR-T, and multi-target CAR-T therapies for solid tumors.
Company Information
Company
Simnova Biotech
Location
Shanghai, China
About
Simnova Biotech is a Chinese cell therapy startup founded in 2019, originally spun off from Simcere Pharmaceutical Group. The company focuses on developing off-the-shelf cell therapies using three technology platforms: CAR-NK, In Vivo CAR-T, and multi-target CAR-T therapies for solid tumors. Its lead program SNC103 is a CAR-NK cell therapy that has shown positive results in Phase I trials for systemic lupus erythematosus.
Don't miss Simnova Biotech's next move
Get an email the moment Simnova Biotech raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Simnova Biotech's next move
ShanghaiBiotechnology